Identification

Name
Droperidol
Accession Number
DB00450  (APRD00939)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)

Structure
Thumb
Synonyms
  • 1-(1-(3-(P-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
  • 1-(1-(4-(P-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
  • 1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one
  • 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[D]imidazol-2-one
  • Droperidol
  • Dropéridol
  • Droperidolo
  • Droperidolum
External IDs
McN-JR 4749 / MCN-JR-4749 / R 4749 / R-4749
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Droperidol InjectionLiquid2.5 mgIntramuscular; IntravenousNovopharm Limited1998-04-202002-03-14Canada
Droperidol Injection USP 2.5mg/mlSolution2.5 mgIntramuscular; IntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
InapsineInjection2.5 mg/mLIntramuscular; IntravenousAkorn1996-07-012016-11-15Us
InapsineInjection2.5 mg/mLIntramuscular; IntravenousAkorn1996-07-012016-11-15Us
Inapsine Inj 2.5mg/mlLiquid2.5 mgIntramuscular; IntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1982-12-311998-08-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2012-10-182017-01-19Us
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousHospira, Inc.1988-02-29Not applicableUs
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousCardinal Health1990-09-302018-01-31Us
DroperidolInjection, solution2.5 mg/mLIntramuscular; IntravenousAmerican Regent1990-09-30Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Innovar InjDroperidol (2.5 mg) + Fentanyl citrate (.05 mg)LiquidIntramuscular; IntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1982-12-311996-09-10Canada
International/Other Brands
Dehydrobenzperidol (Janssen) / Dridol (Prostrakan) / Droleptan (Daiichi Sankyo) / Dropedol (Excelsior) / Dropel (Siu Guan) / Droperdal (Cristália) / Droperidols (Grindeks) / Xomolix (Arzneimittel ProStrakan)
Categories
UNII
O9U0F09D5X
CAS number
548-73-2
Weight
Average: 379.4274
Monoisotopic: 379.169605168
Chemical Formula
C22H22FN3O2
InChI Key
RMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
IUPAC Name
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12

Pharmacology

Indication

Droperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.

Associated Conditions
Associated Therapies
Pharmacodynamics

Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias.

Mechanism of action

The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine(2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
Absorption

Completely absorbed following intramuscular administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Extensively metabolized.

Route of elimination
Not Available
Half life

Biphasic distribution. The rapid distribution phase is 1.4 ± 0.5 minutes and the slower distribution phase is 14.3 ± 6.5 minutes. Elimination half-life in adults is 134 ± 13 minutes and may be increased in geriatric patients. In children, it is 101.5 ± 26.4 minutes.

Clearance
Not Available
Toxicity

The intravenous LD50 of droperidol is 20-43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11-13 mg/kg in rabbits. The intramuscular LD50 of droperidol is 195 mg/kg in mice, 104-110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs. The manifestations of droperidol overdosage are an extension of its pharmacologic actions.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineDroperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineDroperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineDroperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineDroperidol may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
AcepromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AdipiplonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AdrafinilDroperidol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Droperidol.Experimental, Investigational
AgomelatineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Droperidol is combined with Alaproclate.Experimental
AlfaxaloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Droperidol.Approved, Investigational
AllopregnanoloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Droperidol.Approved, Investigational
AlphacetylmethadolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Amantadine.Approved
AmibegronDroperidol may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Amiodarone.Approved, Investigational
AmisulprideDroperidol may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazDroperidol may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Droperidol is combined with Amlodipine.Approved
AmobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineDroperidol may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Droperidol is combined with Amrinone.Approved
AnagrelideDroperidol may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineDroperidol may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineDroperidol may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Aranidipine.Approved, Investigational
ArbutamineDroperidol may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
AripiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Droperidol.Investigational
Arsenic trioxideDroperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDroperidol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Droperidol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Droperidol.Approved
AvanafilAvanafil may increase the hypotensive activities of Droperidol.Approved
AzaperoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Droperidol is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Droperidol.Approved
BaclofenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BambuterolDroperidol may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Barnidipine.Approved
BedaquilineDroperidol may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Droperidol.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Droperidol is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Benidipine.Approved, Investigational
BenperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Droperidol.Approved
BenzphetamineDroperidol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholDroperidol may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
BevantololDroperidol may increase the antihypertensive activities of Bevantolol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Droperidol is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Droperidol.Approved
BitolterolDroperidol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Droperidol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
BrexpiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Investigational
BrimonidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit, Investigational
BromisovalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Approved, Investigational
BrompheniramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Droperidol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Droperidol.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Droperidol.Investigational
BupivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Droperidol.Approved
BuprenorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
BuspironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Withdrawn
ButethalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Droperidol.Approved
CanertinibDroperidol may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
CarbamazepineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Droperidol is combined with Carboxyamidotriazole.Investigational
CarfentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Droperidol is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Droperidol.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Droperidol.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
CeritinibDroperidol may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit, Investigational
ChlormezanoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChloroquineDroperidol may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorphentermineDroperidol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CilnidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Cilnidipine.Approved, Investigational
CinchocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Droperidol is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Ciprofloxacin.Approved, Investigational
CirazolineDroperidol may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideDroperidol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramDroperidol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinDroperidol may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved, Investigational
ClenbuterolDroperidol may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Clevidipine.Approved, Investigational
ClidiniumDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClindamycinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clindamycin.Approved, Vet Approved
ClobazamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Investigational, Vet Approved
ClonazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopenthixolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Droperidol.Experimental
ClorazepateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClothiapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
ClozapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
CrizotinibDroperidol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclandelateThe risk or severity of hypotension can be increased when Droperidol is combined with Cyclandelate.Approved
CyclizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclopropaneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclopropane.Experimental
CyclosporineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
DantroleneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Investigational
DapiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Droperidol.Investigational
DarodipineThe risk or severity of hypotension can be increased when Droperidol is combined with Darodipine.Experimental
DasatinibDasatinib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Droperidol.Approved
DelamanidDroperidol may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeramciclaneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DesfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Investigational
DesloratadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desvenlafaxine.Approved, Investigational
DetomidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DeutetrabenazineDroperidol may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexbrompheniramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Droperidol is combined with Dexniguldipine.Experimental
DextroamphetamineDroperidol may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Droperidol.Approved
DextromoramideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe risk or severity of hypotension can be increased when Droperidol is combined with Dexverapamil.Experimental
DezocineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
DiethylpropionDroperidol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Droperidol.Approved, Investigational
DihydroetorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Droperidol is combined with Diltiazem.Approved, Investigational
DimenhydrinateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Investigational
DiphenoxylateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DipivefrinDroperidol may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Droperidol.Approved
DisopyramideDroperidol may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
DL-MethylephedrineDroperidol may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineDroperidol may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideDroperidol may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronDroperidol may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneDroperidol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineDroperidol may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DotarizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dotarizine.Investigational
DoxazosinDoxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Droperidol.Approved
DoxepinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved, Investigational
DoxofyllineDroperidol may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Vet Approved
DPDPEDroperidol may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Illicit
DronedaroneDroperidol may increase the QTc-prolonging activities of Dronedarone.Approved
DrotebanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DroxidopaDroperidol may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Droperidol is combined with Duloxetine.Approved
DyclonineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EcopipamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzDroperidol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Droperidol.Approved, Investigational
EliglustatDroperidol may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EmopamilThe risk or severity of hypotension can be increased when Droperidol is combined with Emopamil.Experimental
EnfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EntacaponeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Droperidol.Experimental
EperisoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Eperisone.Approved, Investigational
EphedraDroperidol may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDroperidol may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineDroperidol may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineDroperidol may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Droperidol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Droperidol.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Droperidol.Experimental
EscitalopramDroperidol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Droperidol.Approved
EstazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Investigational
EtafedrineDroperidol may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtilefrineDroperidol may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Etoperidone.Withdrawn
EtorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Droperidol.Approved
FelbamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineThe risk or severity of hypotension can be increased when Droperidol is combined with Felodipine.Approved, Investigational
FencamfamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Droperidol is combined with Fendiline.Withdrawn
FenoterolDroperidol may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Droperidol is combined with Fish oil.Approved, Nutraceutical
FlecainideDroperidol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Investigational
FluanisoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
FludiazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved, Vet Approved
FlupentixolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit, Investigational
FluspirileneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FluvoxamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Droperidol.Approved
FosphenytoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved, Investigational
FospropofolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Droperidol.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Droperidol.Approved, Investigational
GabapentinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidDroperidol may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Droperidol.Approved
GallopamilThe risk or severity of hypotension can be increased when Droperidol is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemifloxacinDroperidol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineDroperidol may decrease the stimulatory activities of Gepefrine.Experimental
GepironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Droperidol.Approved
GranisetronDroperidol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzDroperidol may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HexoprenalineDroperidol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineDroperidol may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Droperidol.Approved
HydrocodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyamphetamineDroperidol may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
IbutilideDroperidol may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Droperidol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Droperidol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Droperidol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Droperidol.Withdrawn
IndiplonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Droperidol.Withdrawn
Iofetamine I-123Droperidol may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Droperidol can be increased when used in combination with Isocarboxazid.Approved
IsoetarineDroperidol may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsomethepteneDroperidol may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineDroperidol may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineDroperidol may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Droperidol is combined with Isradipine.Approved, Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Droperidol.Approved
KetamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Droperidol.Approved
LacidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Lacidipine.Approved, Investigational
LamotrigineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Droperidol.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
LenvatinibDroperidol may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
LevetiracetamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
LevobupivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved, Investigational
LevocetirizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
LevofloxacinDroperidol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Droperidol is combined with Levomilnacipran.Approved, Investigational
LevorphanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevosalbutamolDroperidol may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Droperidol is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Droperidol.Approved, Investigational
LisdexamfetamineDroperidol may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Lithium cationDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lithium.Experimental
LofentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Droperidol can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe risk or severity of hypotension can be increased when Droperidol is combined with Lomerizine.Experimental
LoperamideThe risk or severity of hypotension can be increased when Droperidol is combined with Loperamide.Approved
LopinavirDroperidol may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Investigational
LorazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Droperidol.Approved
LormetazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LoxapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LumefantrineDroperidol may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Investigational
MacimorelinDroperidol may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
Magnesium carbonateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium carbonate.Approved, Investigational
Magnesium citrateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium citrate.Approved
Magnesium hydroxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved, Investigational
Magnesium sulfateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved
ManidipineThe risk or severity of hypotension can be increased when Droperidol is combined with Manidipine.Approved, Investigational
MaprotilineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Investigational
MebicarDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MeclizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
MelatoninDroperidol may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Droperidol is combined with Menthol.Approved
MephedroneDroperidol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineDroperidol may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Droperidol.Experimental
MepivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Droperidol.Approved, Vet Approved
MequitazineDroperidol may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MetaraminolDroperidol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethamphetamineDroperidol may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineDroperidol may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineDroperidol may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethyldopaDroperidol may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Droperidol is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Droperidol.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol.Approved
MibefradilThe risk or severity of hypotension can be increased when Droperidol is combined with Mibefradil.Investigational, Withdrawn
MidazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MidodrineDroperidol may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineDroperidol may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneDroperidol may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Droperidol is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Droperidol.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Droperidol.Investigational
MirtazapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDADroperidol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Droperidol.Approved
MolindoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Droperidol.Approved, Investigational
MoxonidineDroperidol may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Droperidol.Approved
NaftopidilThe risk or severity of hypotension can be increased when Droperidol is combined with Naftopidil.Investigational
NalbuphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Droperidol.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Droperidol.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Droperidol.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Droperidol.Approved
NeomycinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Neomycin.Approved, Vet Approved
NicardipineNicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Droperidol.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Droperidol.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Droperidol is combined with Nifedipine.Approved
NiguldipineDroperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Niguldipine.Experimental
NilotinibDroperidol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Droperidol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Droperidol is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Droperidol is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Droperidol is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Droperidol is combined with Nisoldipine.Approved
NitrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineThe risk or severity of hypotension can be increased when Droperidol is combined with Nitrendipine.Approved, Investigational
Nitrous oxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NordazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nordazepam.Approved
NorepinephrineDroperidol may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineDroperidol may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Droperidol.Approved
NorfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Approved, Investigational
NormethadoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Droperidol.Approved
OctopamineDroperidol may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
OfloxacinDroperidol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Droperidol.Approved
OlopatadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumDroperidol may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrciprenalineDroperidol may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantDroperidol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Droperidol is combined with Otilonium.Experimental, Investigational
OxazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxprenololDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved, Investigational
OxycodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxyfedrineDroperidol may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Droperidol.Approved, Investigational
OxymorphoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
PaliperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PanobinostatDroperidol may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Droperidol.Approved
PazopanibDroperidol may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
PenfluridolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PentamidineDroperidol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Droperidol.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved
PerazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Investigational
PerflutrenDroperidol may increase the QTc-prolonging activities of Perflutren.Approved
PergolideDroperidol may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhendimetrazineDroperidol may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.Approved
PhenibutDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Droperidol.Approved
PhenobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Investigational
PhenoperidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Droperidol.Approved
PhenoxyethanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhentermineDroperidol may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineDroperidol may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Droperidol.Approved
PhenylpropanolamineDroperidol may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Droperidol is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
PipamperoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipotiazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PirbuterolDroperidol may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Droperidol can be decreased when used in combination with Piribedil.Investigational
PiritramideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Approved, Investigational
PitolisantThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Pitolisant.Approved, Investigational
PizotifenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Droperidol.Experimental
Polymyxin B SulfateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Droperidol.Approved
PramipexoleDroperidol may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Droperidol.Approved
PregabalinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolDroperidol may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Droperidol is combined with Prenylamine.Withdrawn
PrilocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimaquineDroperidol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcainamideDroperidol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Droperidol.Approved, Investigational
ProcaterolDroperidol may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Droperidol.Approved
PropanididDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
ProparacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropericiazineDroperidol may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Droperidol.Approved
PropiverineDroperidol may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Investigational
ProtokylolDroperidol may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PSD502Droperidol may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PseudoephedrineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved
PyrantelDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pyrantel.Approved, Vet Approved
QuazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Droperidol.Approved, Investigational
QuinidineDroperidol may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineDroperidol may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacepinephrineDroperidol may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RactopamineDroperidol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.Approved
RemifentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReproterolDroperidol may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Droperidol.Approved, Investigational
RilmenidineDroperidol may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Droperidol.Approved
RimiterolDroperidol may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitobegronDroperidol may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineDroperidol may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
RizatriptanDroperidol may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.Approved
RomifidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleDroperidol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineDroperidol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Droperidol.Approved
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Droperidol.Approved, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Droperidol.Approved
SaquinavirDroperidol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
SecobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Droperidol.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Droperidol is combined with Seletracetam.Investigational
SepranoloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SertindoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Droperidol is combined with Sertraline.Approved
SevofluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Droperidol.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Droperidol.Approved
Sodium oxybateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SolabegronDroperidol may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Droperidol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
SotalolDroperidol may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SufentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Droperidol.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
SulpirideDroperidol may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SumatriptanDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
SuvorexantDroperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineDroperidol may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Droperidol.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Droperidol.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Droperidol.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Droperidol.Approved, Investigational
TandospironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved
TasimelteonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Droperidol.Approved
TelavancinDroperidol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinDroperidol may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Droperidol.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Droperidol.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Droperidol.Experimental
TetrabenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Investigational
TetracaineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of hypotension can be increased when Droperidol is combined with Tetrandrine.Experimental
TetrodotoxinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
TetryzolineDroperidol may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Droperidol.Approved
ThiamylalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioproperazineDroperidol may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Investigational
TiaprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TiletamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Droperidol.Approved
TizanidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
TolcaponeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Droperidol is combined with Tolfenamic Acid.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
TopiramateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
ToremifeneDroperidol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Droperidol is combined with Tranilast.Approved, Investigational
TranylcypromineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
TrazodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
TretoquinolDroperidol may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved, Investigational
Tricaine methanesulfonateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichloroethyleneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Approved
TrifluoperazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Investigational
TrifluperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Droperidol.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Droperidol is combined with Trimebutine.Approved
TrimethadioneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
TrimipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
TulobuterolDroperidol may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Droperidol.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Droperidol.Investigational
Valproic AcidDroperidol may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VandetanibDroperidol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Droperidol.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Droperidol.Approved
VenlafaxineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Venlafaxine.Approved
VeraliprideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VerapamilDroperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
VigabatrinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Droperidol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Droperidol.Approved
VinpocetineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine.Investigational
Vinyl etherDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Droperidol.Approved, Investigational
VortioxetineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Droperidol is combined with WIN 55212-2.Experimental
XamoterolDroperidol may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XylazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
XylometazolineDroperidol may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Zimelidine.Withdrawn
ZiprasidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolmitriptanDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan.Approved, Investigational
ZolpidemDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium. Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3161645
General References
Not Available
External Links
Human Metabolome Database
HMDB0014593
KEGG Drug
D00308
PubChem Compound
3168
PubChem Substance
46505291
ChemSpider
3056
BindingDB
50017705
ChEBI
4717
ChEMBL
CHEMBL1108
Therapeutic Targets Database
DAP000412
PharmGKB
PA449422
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Droperidol
ATC Codes
N05AD08 — Droperidol
AHFS Codes
  • 28:24.92 — Miscellaneous Anxiolytics Sedatives and Hypnotics
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionPostoperative Emesis / Prophylaxis against postoperative nausea and vomiting1
3CompletedTreatmentInteraction Between Antiemetic Drugs and Paracetamol1
3CompletedTreatmentPain1
3Unknown StatusTreatmentPsychosis Nos/Other1
4CompletedPreventionCardiac Repolarization1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedPreventionVomiting1
4Not Yet RecruitingTreatmentInguinal Hernias / Postoperative pain1
4RecruitingTreatmentHallux Valgus1
4TerminatedPreventionNausea / Vomiting1
4Unknown StatusTreatmentCholecystolithiasis1
Not AvailableCompletedNot AvailableSchizophrenic Disorders1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting2
Not AvailableCompletedTreatmentMyocardial Repolarization1
Not AvailableTerminatedTreatmentPrimary Headaches (Includes Migraines, Tension, Cluster Headaches)1

Pharmacoeconomics

Manufacturers
  • Abraxis pharmaceutical products
  • Astrazeneca lp
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Solopak laboratories inc
  • Watson laboratories inc
  • Akorn inc
Packagers
  • Akorn Inc.
  • American Regent
  • Cardinal Health
  • Hospira Inc.
  • Luitpold Pharmaceuticals Inc.
  • Neuman Distributors Inc.
  • Physicians Total Care Inc.
  • Taylor Pharmaceuticals
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous2.5 mg/mL
SolutionIntramuscular; Intravenous2.5 mg
InjectionIntramuscular; Intravenous2.5 mg/mL
LiquidIntramuscular; Intravenous2.5 mg
LiquidIntramuscular; Intravenous
Prices
Unit descriptionCostUnit
Inapsine 2.5 mg/ml ampul4.59USD ml
Droperidol 2.5 mg/ml vial2.04USD ml
Droperidol 2.5 mg/ml ampul0.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)145-146.5Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium. Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility4.21 mg/LNot Available
logP3.50SANGSTER (1993)
pKa7.46SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0966 mg/mLALOGPS
logP3.93ALOGPS
logP3.01ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.72ChemAxon
pKa (Strongest Basic)6.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.65 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity109.52 m3·mol-1ChemAxon
Polarizability40.31 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9602
Caco-2 permeable-0.7521
P-glycoprotein substrateSubstrate0.7471
P-glycoprotein inhibitor IInhibitor0.9128
P-glycoprotein inhibitor IIInhibitor0.7451
Renal organic cation transporterInhibitor0.67
CYP450 2C9 substrateNon-substrate0.7884
CYP450 2D6 substrateNon-substrate0.8756
CYP450 3A4 substrateSubstrate0.6751
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9279
Ames testNon AMES toxic0.6353
CarcinogenicityNon-carcinogens0.9104
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5820 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8955
hERG inhibition (predictor II)Inhibitor0.835
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0209000000-83800a9c755f8223f328
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-418e20f120e395aac71a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-2888306b46b834e3dd3b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-0cff909ec834cc05a2d3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00xr-0900000000-f910b21f009854002b17
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001l-0609000000-b071b906d4d1f94ae833
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-0900000000-ac3d815681b1b57a53b5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-b2c3fb5ea6889dbf960c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00xr-0900000000-01bdbb9758cd0acb8864
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-09ecdeee9f023e5ac679
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-be69940105e80f5ab869
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-2900000000-9a55a536e908d6236924
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00fr-9800000000-4462513b0f99ffd6ce93
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00b9-9200000000-b61d87593ee28d4b283e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0918000000-1efb9a7c97db08bb65d2
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2900000000-dd5f00934e38a7c6ddbb

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylbutylamines / Butyrophenones / Benzimidazoles / Aryl alkyl ketones / Benzoyl derivatives / Fluorobenzenes / Aryl fluorides / N-substituted imidazoles / Hydropyridines / Gamma-amino ketones
show 8 more
Substituents
Alkyl-phenylketone / Phenylbutylamine / Butyrophenone / Benzimidazole / Benzoyl / Aryl alkyl ketone / Halobenzene / Fluorobenzene / Aryl fluoride / Aryl halide
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, aromatic ketone, benzimidazoles (CHEBI:4717)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Grip G, Svensson BA, Gordh T Jr, Post C, Hartvig P: Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat. Acta Anaesthesiol Scand. 1992 Feb;36(2):145-52. [PubMed:1549935]
  2. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092]
  3. Larson MD: The effect of antiemetics on pupillary reflex dilation during epidural/general anesthesia. Anesth Analg. 2003 Dec;97(6):1652-6. [PubMed:14633536]
  4. Gao HR, Shi TF, Yang CX, Zhang D, Zhang GW, Zhang Y, Jiao RS, Zhang H, Xu MY: The effect of dopamine on pain-related neurons in the parafascicular nucleus of rats. J Neural Transm (Vienna). 2010 May;117(5):585-91. doi: 10.1007/s00702-010-0398-3. Epub 2010 Apr 1. [PubMed:20358234]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Zupko I, Janossy K, Maul K, Marki A, Falkay G: Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. [PubMed:12505540]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:20